{"entity":{"type":"insider","cik":"0001629472","url":"/insider/0001629472","json_url":"/insider/0001629472.json","name":"Viking Global Opportunities Portfolio GP LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":106,"n_filings":44,"first":"2016-02-08","last":"2025-10-09","span_basis":"filed_date"},"name_variants":[{"name":"Viking Global Opportunities Portfolio GP LLC","source":"filing","n_filings":44,"first_seen":"2016-02-08","last_seen":"2025-10-09"}],"transactions":[{"id":4831304,"accession":"0000905148-25-003555","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000905148-25-003555","line_url":"/filing/0000905148-25-003555","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":350000.0,"shares_display":"350,000","price_per_share":32.25,"price_display":"32.25","price_state":"stated","total_value":11287500.0,"total_display":"11,287,500.00","total_whole":"11,287,500","shares_owned_after":1267823.0,"shares_owned_after_display":"1,267,823","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-07","filed_date":"2025-10-09","scope":"insider","n_lines":3},{"id":4369894,"accession":"0000905148-25-002297","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-25-002297","line_url":"/filing/0000905148-25-002297#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500000.0,"shares_display":"3,500,000","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":154000000.0,"total_display":"154,000,000.00","total_whole":"154,000,000","shares_owned_after":18555375.0,"shares_owned_after_display":"18,555,375","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider"},{"id":4977966,"accession":"0000905148-25-000306","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-25-000306","line_url":"/filing/0000905148-25-000306#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3065616.0,"shares_display":"3,065,616","price_per_share":34.9,"price_display":"34.90","price_state":"stated","total_value":106989998.4,"total_display":"106,989,998.40","total_whole":"106,989,998","shares_owned_after":22055375.0,"shares_owned_after_display":"22,055,375","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-01-31","filed_date":"2025-01-31","scope":"insider"},{"id":2816979,"accession":"0000905148-24-001733","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-24-001733","line_url":"/filing/0000905148-24-001733","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1951782.0,"shares_display":"1,951,782","price_per_share":38.15,"price_display":"38.15","price_state":"stated","total_value":74460483.3,"total_display":"74,460,483.30","total_whole":"74,460,483","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-06-17","filed_date":"2024-06-18","scope":"insider","n_lines":2},{"id":2579262,"accession":"0000905148-24-000920","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-24-000920","line_url":"/filing/0000905148-24-000920","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3038617.0,"shares_display":"3,038,617","price_per_share":34.25,"price_display":"34.25","price_state":"stated","total_value":104072632.25,"total_display":"104,072,632.25","total_whole":"104,072,632","shares_owned_after":1912750.0,"shares_owned_after_display":"1,912,750","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-05","filed_date":"2024-03-07","scope":"insider","n_lines":2},{"id":3149962,"accession":"0000905148-24-000092","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-24-000092","line_url":"/filing/0000905148-24-000092#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":540000.0,"shares_display":"540,000","price_per_share":19.53,"price_display":"19.53","price_state":"stated","total_value":10546200.0,"total_display":"10,546,200.00","total_whole":"10,546,200","shares_owned_after":4247914.0,"shares_owned_after_display":"4,247,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-04","filed_date":"2024-01-05","scope":"insider"},{"id":2267848,"accession":"0000905148-24-000080","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000905148-24-000080","line_url":"/filing/0000905148-24-000080","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"APi Group Corp","issuer_ticker":"APG","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6500000.0,"shares_display":"6,500,000","price_per_share":31.3,"price_display":"31.30","price_state":"stated","total_value":203450000.0,"total_display":"203,450,000.00","total_whole":"203,450,000","shares_owned_after":27032516.0,"shares_owned_after_display":"27,032,516","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider","n_lines":3},{"id":7993614,"accession":"0000905148-23-000958","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000905148-23-000958","line_url":"/filing/0000905148-23-000958","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"RayzeBio, Inc.","issuer_ticker":"RYZB","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1388889.0,"shares_display":"1,388,889","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":25000002.0,"total_display":"25,000,002.00","total_whole":"25,000,002","shares_owned_after":4899144.0,"shares_owned_after_display":"4,899,144","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-21","scope":"insider","n_lines":2},{"id":8571685,"accession":"0001140361-23-035288","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-23-035288","line_url":"/filing/0001140361-23-035288#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500000.0,"shares_display":"1,500,000","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":52500000.0,"total_display":"52,500,000.00","total_whole":"52,500,000","shares_owned_after":25120991.0,"shares_owned_after_display":"25,120,991","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-18","filed_date":"2023-07-19","scope":"insider"},{"id":8323411,"accession":"0001140361-23-031459","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-23-031459","line_url":"/filing/0001140361-23-031459","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13000000.0,"shares_display":"13,000,000","price_per_share":9.9,"price_display":"9.90","price_state":"stated","total_value":128700000.0,"total_display":"128,700,000.00","total_whole":"128,700,000","shares_owned_after":31409512.0,"shares_owned_after_display":"31,409,512","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-26","scope":"insider","n_lines":4},{"id":8033916,"accession":"0001140361-23-024202","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-23-024202","line_url":"/filing/0001140361-23-024202#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":850000.0,"shares_display":"850,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":13600000.0,"total_display":"13,600,000.00","total_whole":"13,600,000","shares_owned_after":4787914.0,"shares_owned_after_display":"4,787,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-09","filed_date":"2023-05-11","scope":"insider"},{"id":6141346,"accession":"0001140361-22-040057","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-22-040057","line_url":"/filing/0001140361-22-040057","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Frazier Lifesciences Acquisition Corp","issuer_ticker":"FLAC","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":847062.0,"shares_display":"847,062","price_per_share":10.08,"price_display":"10.08","price_state":"stated","total_value":8538384.96,"total_display":"8,538,384.96","total_whole":"8,538,385","shares_owned_after":2459880.0,"shares_owned_after_display":"2,459,880","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-02","filed_date":"2022-11-04","scope":"insider","n_lines":2},{"id":6667180,"accession":"0001140361-22-036956","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-22-036956","line_url":"/filing/0001140361-22-036956","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"DRAGSA 50 LLC; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"DRAGSA 50 LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1333333.0,"shares_display":"1,333,333","price_per_share":29.9999,"price_display":"30.00","price_state":"stated","total_value":39999856.6667,"total_display":"39,999,856.67","total_whole":"39,999,857","shares_owned_after":2427307.0,"shares_owned_after_display":"2,427,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-07","filed_date":"2022-10-12","scope":"insider","n_lines":2},{"id":6445130,"accession":"0001140361-22-032970","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001140361-22-032970","line_url":"/filing/0001140361-22-032970","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"DRAGSA 96 LLC; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"DRAGSA 96 LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700000.0,"shares_display":"700,000","price_per_share":30.228218203714285,"price_display":"30.23","price_state":"stated","total_value":21159752.7426,"total_display":"21,159,752.74","total_whole":"21,159,753","shares_owned_after":4082713.0,"shares_owned_after_display":"4,082,713","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-09","filed_date":"2022-09-09","scope":"insider","n_lines":6},{"id":6445104,"accession":"0001140361-22-032970","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001140361-22-032970","line_url":"/filing/0001140361-22-032970","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"DRAGSA 96 LLC; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"DRAGSA 96 LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700000.0,"shares_display":"700,000","price_per_share":29.37126653085714,"price_display":"29.37","price_state":"stated","total_value":20559886.5716,"total_display":"20,559,886.57","total_whole":"20,559,887","shares_owned_after":4522164.0,"shares_owned_after_display":"4,522,164","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-08","filed_date":"2022-09-09","scope":"insider","n_lines":10},{"id":6205833,"accession":"0000905148-22-000308","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-22-000308","line_url":"/filing/0000905148-22-000308","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"PROCEPT BioRobotics Corp","issuer_ticker":"PRCT","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"DRAGSA 88 LLC; HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"DRAGSA 88 LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1249000.0,"shares_display":"1,249,000","price_per_share":29.9,"price_display":"29.90","price_state":"stated","total_value":37345100.0,"total_display":"37,345,100.00","total_whole":"37,345,100","shares_owned_after":3360687.0,"shares_owned_after_display":"3,360,687","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-18","filed_date":"2022-03-22","scope":"insider","n_lines":2},{"id":6818387,"accession":"0001140361-22-001654","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-22-001654","line_url":"/filing/0001140361-22-001654#line-2","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"HALVORSEN OLE ANDREAS","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2300000.0,"shares_display":"2,300,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":43700000.0,"total_display":"43,700,000.00","total_whole":"43,700,000","shares_owned_after":2300000.0,"shares_owned_after_display":"2,300,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider"},{"id":5497159,"accession":"0001567619-21-017393","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-21-017393","line_url":"/filing/0001567619-21-017393#line-4","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"PROCEPT BioRobotics Corp","issuer_ticker":"PRCT","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"Viking Global Opportunities Portfolio GP LLC; VIKING GLOBAL INVESTORS LP; HALVORSEN OLE ANDREAS; Viking Global Opportunities GP LLC; Shabet Rose Sharon; Ott David C.; DRAGSA 88 LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP","owner_display_name":"Viking Global Opportunities Portfolio GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":14000000.0,"total_display":"14,000,000.00","total_whole":"14,000,000","shares_owned_after":400000.0,"shares_owned_after_display":"400,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-17","filed_date":"2021-09-21","scope":"insider"},{"id":4277008,"accession":"0001567619-21-016763","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-016763","line_url":"/filing/0001567619-21-016763#line-2","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"FIGS, Inc.","issuer_ticker":"FIGS","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities GP LLC; VIKING GLOBAL INVESTORS LP; Ott David C.; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42413.0,"shares_display":"42,413","price_per_share":44.92,"price_display":"44.92","price_state":"stated","total_value":1905191.96,"total_display":"1,905,191.96","total_whole":"1,905,192","shares_owned_after":14742689.0,"shares_owned_after_display":"14,742,689","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-03","filed_date":"2021-09-03","scope":"insider"},{"id":4277002,"accession":"0001567619-21-016763","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-016763","line_url":"/filing/0001567619-21-016763#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"FIGS, Inc.","issuer_ticker":"FIGS","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities GP LLC; VIKING GLOBAL INVESTORS LP; Ott David C.; Shabet Rose Sharon; HALVORSEN OLE ANDREAS; Viking Global Opportunities Portfolio GP LLC","owner_display_name":"Viking Global Opportunities Illiquid Investments Sub-Master LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":157587.0,"shares_display":"157,587","price_per_share":47.28,"price_display":"47.28","price_state":"stated","total_value":7450713.36,"total_display":"7,450,713.36","total_whole":"7,450,713","shares_owned_after":14785102.0,"shares_owned_after_display":"14,785,102","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-02","filed_date":"2021-09-03","scope":"insider"},{"id":5483142,"accession":"0001387131-21-007995","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-21-007995","line_url":"/filing/0001387131-21-007995#line-2","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Rallybio Corp","issuer_ticker":"RLYB","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"Viking Global Opportunities GP LLC; Ott David C.; VIKING GLOBAL INVESTORS LP; HALVORSEN OLE ANDREAS; Viking Global Opportunities Portfolio GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Shabet Rose Sharon","owner_display_name":"Viking Global Opportunities GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":806000.0,"shares_display":"806,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":10478000.0,"total_display":"10,478,000.00","total_whole":"10,478,000","shares_owned_after":4194777.0,"shares_owned_after_display":"4,194,777","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-29","filed_date":"2021-08-02","scope":"insider"},{"id":2154524,"accession":"0001387131-20-011272","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001387131-20-011272","line_url":"/filing/0001387131-20-011272#line-3","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"4D Molecular Therapeutics Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"Shabet Rose Sharon; HALVORSEN OLE ANDREAS; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities Portfolio GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Ott David C.; Viking Global Opportunities GP LLC","owner_display_name":"Shabet Rose Sharon","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1100000.0,"shares_display":"1,100,000","price_per_share":23.0,"price_display":"23.00","price_state":"stated","total_value":25300000.0,"total_display":"25,300,000.00","total_whole":"25,300,000","shares_owned_after":3937914.0,"shares_owned_after_display":"3,937,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-17","scope":"insider"},{"id":2060695,"accession":"0001387131-20-010443","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-20-010443","line_url":"/filing/0001387131-20-010443#line-1","is_derivative":false,"issuer_cik":"0001103804","issuer_name":"Zentalis Pharmaceuticals, Inc.","issuer_ticker":"ZNTL","issuer_name_source":null,"issuer_url":"/issuer/0001103804","owner_cik":null,"owner_name":"Viking Global Opportunities Portfolio GP LLC; Viking Global Opportunities GP LLC; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; HALVORSEN OLE ANDREAS; Ott David C.; Viking Global Opportunities Illiquid Investments Sub-Master LP","owner_display_name":"Viking Global Opportunities Portfolio GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":50.5,"price_display":"50.50","price_state":"stated","total_value":25250000.0,"total_display":"25,250,000.00","total_whole":"25,250,000","shares_owned_after":3943284.0,"shares_owned_after_display":"3,943,284","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-01","filed_date":"2020-12-03","scope":"insider"}],"collapsed":true,"next_cursor":"2020-12-01|2060695","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002007919","name":"Inhibrx Biosciences, Inc.","url":"/issuer/0002007919","role":"Ten percent owner","n_filings":1,"first_seen":"2025-10-09","last_seen":"2025-10-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001743881","name":"BridgeBio Pharma, Inc.","url":"/issuer/0001743881","role":"Ten percent owner","n_filings":4,"first_seen":"2019-06-28","last_seen":"2025-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001796209","name":"APi Group Corp","url":"/issuer/0001796209","role":"Ten percent owner","n_filings":3,"first_seen":"2024-01-04","last_seen":"2024-06-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001650648","name":"4D Molecular Therapeutics, Inc.","url":"/issuer/0001650648","role":"Ten percent owner","n_filings":3,"first_seen":"2020-12-17","last_seen":"2024-01-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001825367","name":"RayzeBio, Inc.","url":"/issuer/0001825367","role":"Ten percent owner","n_filings":1,"first_seen":"2023-09-21","last_seen":"2023-09-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001635088","name":"Roivant Sciences Ltd.","url":"/issuer/0001635088","role":"Ten percent owner","n_filings":1,"first_seen":"2023-06-26","last_seen":"2023-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001828326","name":"Frazier Lifesciences Acquisition Corp","url":"/issuer/0001828326","role":"Ten percent owner","n_filings":1,"first_seen":"2022-11-04","last_seen":"2022-11-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001739614","name":"Inhibrx, Inc.","url":"/issuer/0001739614","role":"Ten percent owner","n_filings":3,"first_seen":"2020-08-25","last_seen":"2022-10-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001658551","name":"Amylyx Pharmaceuticals, Inc.","url":"/issuer/0001658551","role":"Ten percent owner","n_filings":2,"first_seen":"2022-01-13","last_seen":"2022-09-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001588978","name":"PROCEPT BioRobotics Corp","url":"/issuer/0001588978","role":"Ten percent owner","n_filings":2,"first_seen":"2021-09-21","last_seen":"2022-03-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001846576","name":"FIGS, Inc.","url":"/issuer/0001846576","role":"Ten percent owner","n_filings":1,"first_seen":"2021-09-03","last_seen":"2021-09-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001739410","name":"Rallybio Corp","url":"/issuer/0001739410","role":"Ten percent owner","n_filings":1,"first_seen":"2021-08-02","last_seen":"2021-08-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001725160","name":"Zentalis Pharmaceuticals, Inc.","url":"/issuer/0001725160","role":"Ten percent owner","n_filings":2,"first_seen":"2020-04-08","last_seen":"2020-12-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001478320","name":"Adaptive Biotechnologies Corp","url":"/issuer/0001478320","role":"Ten percent owner","n_filings":3,"first_seen":"2019-07-02","last_seen":"2020-11-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001740547","name":"Urovant Sciences Ltd.","url":"/issuer/0001740547","role":"Ten percent owner","n_filings":9,"first_seen":"2018-10-03","last_seen":"2019-06-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Ten percent owner","n_filings":2,"first_seen":"2018-04-05","last_seen":"2019-06-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001636050","name":"Axovant Sciences Ltd.","url":"/issuer/0001636050","role":"Ten percent owner","n_filings":3,"first_seen":"2018-06-07","last_seen":"2019-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001650664","name":"Editas Medicine, Inc.","url":"/issuer/0001650664","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2016-02-08","last_seen":"2016-02-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001629472","retrieved_at":"2026-08-22T10:22:13+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}